Isomorphic Labs, a London-based company focused on using artificial intelligence for drug discovery, has raised $2.1 billion in a Series B funding round. This significant investment aims to expand their AI-driven drug design engine and speed up the process of bringing new medicines to market. Founded by Nobel laureate Sir Demis Hassabis in 2021, the